Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
19 Results for "
thromboxane A2 synthase
" in MedChemExpress (MCE) Product Catalog:
Products (19)
19 Results for "thromboxane A2 synthase" in MCE Product Catalog:
1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
1
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
Cat. No.: HY-B1735
CAS No.: 32828-81-2
Target:
Research Areas:
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases .
Cat. No.: HY-19189
CAS No.: 149979-74-8
Synonyms: BIBV 308SE
Target:
Research Areas:
Terbogrel is an orally available thromboxane A2 receptor antagonist and a thromboxane A2 synthase inhibitor, with both IC50s of about 10 nM.
Cat. No.: HY-19132
CAS No.: 134235-78-2
Target:
Research Areas:
CGS 22652 is a potent thromboxane A2 receptor antagonist. CGS 22652 has selective thromboxane A2 synthase inhibitory properties. CGS 22652 can be used in the research of coronary artery thrombosis .
Cat. No.: HY-116281
CAS No.: 147332-48-7
Target:
Research Areas:
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .
Cat. No.: HY-124150
CAS No.: 284464-77-3
Target:
Research Areas:
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively .
Synonyms: U-63557A
Target:
Research Areas:
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
Cat. No.: HY-106080
CAS No.: 85666-24-6
Synonyms: U-63557A free acid
Target:
Research Areas:
Furegrelate (U-63557A free acid) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate is being developed as an antiplatelet agent .
Cat. No.: HY-106080AR
CAS No.: 85666-17-7
Synonyms: U-63557A (Standard)
Research Areas:
Furegrelate (sodium) (Standard) is the analytical standard of Furegrelate (sodium). This product is intended for research and analytical applications. Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent .
Cat. No.: HY-119890
CAS No.: 89667-40-3
Synonyms: CV-4151
Target:
Research Areas:
Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID50 value of 0.04 mg/kg .
Cat. No.: HY-137227
CAS No.: 71154-83-1
Synonyms: 15(R)-Pinanethromboxane A2
Target:
Research Areas:
15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
Cat. No.: HY-B0428BR
CAS No.: 78712-43-3
Synonyms: OKY-046 hydrochloride (Standard)
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
Cat. No.: HY-119890A
CAS No.: 89667-39-0
Synonyms: (Z)-CV-4151
Target:
Research Areas:
(Z)-Isbogrel ((Z)-CV-4151) is a potent thromboxane A2 (TxA2) synthase inhibitor with an IC50 of 0.9 nM. (Z)-Isbogrel inhibits serum TxB2 production, with an ED50 of 0.01 mg/kg upon intravenous administration and an ED50 of 0.05 mg/kg upon oral administration in rats, and it exhibits no PAF receptor antagonistic activity. (Z)-Isbogrel can be used in research related to cardiovascular and cerebrovascular diseases .
Cat. No.: HY-106398
CAS No.: 104333-87-1
Target:
Research Areas:
MED 27 is an inhibitor of thromboxane synthase and thromboxane A2 receptors. MED 27 can inhibit rat platelet aggregation at doses much lower than that of Acetylsalicylic acid (HY-14654) .
Cat. No.: HY-B1735A
CAS No.: 80530-63-8
Target:
Research Areas:
Picotamide monohydrate is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide monohydrate has antiplatelet activity. Picotamide monohydrate promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide monohydrate can be used for researching acute or chronic cardiovascular diseases .
Cat. No.: HY-B0428D
CAS No.: 130952-46-4
Synonyms: (E/Z)-OKY-046 sodium
Target:
Research Areas:
Cardiovascular Disease Neurological Disease Inflammation/Immunology
(E/Z)-Ozagrel sodium [(E/Z)-OKY-046 sodium] is an EZ configuration mixture of Ozagrel sodium (HY-B0428A). Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .
Cat. No.: HY-183483
CAS No.: 75987-18-7
Target:
Research Areas:
OKY-1581 is a potent, orally active and selective thromboxane A2 synthase inhibitor. OKY-1581 inhibits TXA2 synthesis and reduces the generation of its stable metabolite TXB2. OKY-1581 shifts arachidonic acid (MCE HY-109590) metabolism toward the production of prostaglandin E, prostaglandin F and 6-keto-prostaglandin F1α. OKY-1581 modulates the TXA2 / PGI2-related eicosanoid balance and inhibits arachidonic acid-induced platelet aggregation without directly inhibiting the cyclooxygenase step. At high oral doses, OKY-1581 also enhances hepatic peroxisomal β-oxidation and reduces serum triglyceride and cholesterol levels. OKY-1581 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage by reducing TXA2-related vasoconstrictive signaling. OKY-1581 can be used in studies of atherosclerosis, cerebral vasospasm after subarachnoid hemorrhage and cardiovascular diseases .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
